Nephro Care India (NEPHROCARE-SM) Share Price Falls 9.93% to Rs 90.7

Nephro Care India Share Price fell to Rs 90.7 on 02 September 2026, down 9.93% for the day from the previous close of Rs 100.7. The company’s market capitalisation stood at Rs 166.02 crore, keeping it in the Micro Cap category within Healthcare. With the stock also touching an intraday low of Rs 85.35, the move drew attention not only for its size but also for what it may imply about valuation and market positioning.

The available data confirms the price move, the intraday range and turnover of Rs 0.28 crore. It does not identify any company-specific trigger behind the decline. In situations like this, investors usually shift focus from the price move alone to the basic questions: how the session unfolded, where the stock sits on earnings and book-value multiples, and how its profitability compares with the wider Hospital & Healthcare Services benchmark.

That is especially relevant here because Nephro Care India Share Price is attached to a business operating in a sector where listed peers trade across a very wide valuation range. The company’s own ratios place it near the industry median on earnings multiple, below the industry median on book value multiple, and slightly below benchmark medians on return ratios. Those details help frame today’s decline without assuming a reason that has not been disclosed in the supplied data.

Nephro Care India (NEPHROCARE-SM) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 90.7
Previous Close	Rs 100.7
Today's Move	-Rs 10.00 (-9.93%)
Open	Rs 100
High	Rs 100
Low	Rs 85.35
Turnover	Rs 0.28 crore
Market Capitalisation	Rs 166.02 crore
Market Cap Category	Micro Cap

Nephro Care India Share Price closed well below both the opening price and the previous close. The stock opened at Rs 100, which also remained the day high, and then moved down to Rs 85.35 before trading at Rs 90.7. That means early levels did not hold through the session.

The difference between the day high of Rs 100 and the low of Rs 85.35 shows a broad intraday swing. For a Micro Cap company with turnover of Rs 0.28 crore, that kind of range can attract trader attention quickly. Still, the move itself should be separated from any unverified explanation, because the supplied dataset confirms the decline but does not assign a cause.

For readers tracking Nephro Care India Share Price today, the immediate factual takeaway is simple: this was a sharp one-session decline accompanied by a meaningful gap between the session high and low. Whether that turns into stabilisation or continued volatility cannot be inferred from the dataset alone.

Nephro Care India (NEPHROCARE-SM) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 166.02 crore
P/E Ratio	49.28x
P/B Ratio	2.84x
ROE	10.62%
ROCE	14.42%
EPS	Rs 2.04
Book Value Per Share	Rs 35.46
Dividend Yield	0%

Nephro Care India’s reported fundamentals show a company with a P/E ratio of 49.28 and a P/B ratio of 2.84. EPS stands at Rs 2.04 and book value per share at Rs 35.46. Against the current market price of Rs 90.7, the stock is trading above book value, while the earnings multiple indicates that the market is not valuing the business at a low P/E relative to profits.

Profitability metrics are moderate rather than standout in the context of the wider listed industry. ROE is 10.62% and ROCE is 14.42%, suggesting the company is generating returns on capital and equity, but not at the upper end of the benchmark set provided. The dividend yield is shown as 0, meaning the present dataset does not reflect a cash yield at the current price.

For anyone reviewing Nephro Care India Share Price through a fundamentals lens, the key point is that today’s decline does not, by itself, turn the stock into an obviously cheap name on earnings. The stock may appear less expensive on price-to-book than some larger peers, but its profitability ratios also sit below several benchmark medians and major comparables.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Hospital & Healthcare Services
Benchmark Scope	same industry
Company P/E Ratio	49.28x
Benchmark Median P/E	47.77x
Benchmark Average P/E	102.53x
Benchmark P/E Range	7.52x to 1,511.2x
Company P/B Ratio	2.84x
Benchmark Median P/B	4.12x
Benchmark Average P/B	4.71x
Company ROE	10.62%
Benchmark Median ROE	12.88%
Benchmark Average ROE	14.16%
Company ROCE	14.42%
Benchmark Median ROCE	15.77%
Benchmark Average ROCE	3.29%
Company Market Capitalisation	Rs 166.02 crore
Benchmark Median Market Cap	Rs 631.34 crore
Benchmark Average Market Cap	Rs 11,993.34 crore

The sector snapshot covers 64 companies in the same industry and shows how wide the valuation spread is in Hospital & Healthcare Services. Nephro Care India’s P/E of 49.28 is slightly above the median P/E of 47.77 but far below the average P/E of 102.53. That gap between median and average suggests some richly valued outliers in the industry.

On price to book, the company’s 2.84 multiple sits below both the median P/B of 4.12 and the average P/B of 4.71 across 63 companies. On profitability, ROE of 10.62% is below the benchmark median of 12.88% and average of 14.16, while ROCE of 14.42% is below the median of 15.77 but above the stated average of 3.29.

Scale is another important difference. The company’s market capitalisation of Rs 166.02 crore is below the benchmark median market cap of Rs 631.34 crore and far below the average market cap of Rs 11,993.34 crore. So while Nephro Care India Share Price may look optically lower than bigger hospital names in absolute terms, the market-cap comparison shows it belongs to a much smaller part of the listed Healthcare universe.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Apollo Hospitals Enterprise	APOLLOHOSP	1,27,397.52	60.3	13.01	23.54	21.73
MANIPAL HEALTH ENTERPRI L	MANIPALHOS	1,00,297.51	110.12	5.39	12.95	13.93
Max Healthcare Institute	MAXHEALTH	99,176.87	67.27	8.97	14.53	14.97
Fortis Healthcare	FORTIS	68,550.2	65.63	6.77	11.32	14.07
Aster DM Healthcare	ASTERDM	65,881	207.39	13.31	9.32	11.46

The peer set makes the scale gap very clear. Nephro Care India’s market cap of Rs 166.02 crore is far below Apollo Hospitals, Manipal Health, Max Healthcare, Fortis Healthcare and Aster DM Healthcare, all of which run into tens of thousands of crores. That difference matters because larger hospital operators often trade with deeper liquidity and different investor expectations.

On valuation, the company’s P/E of 49.28 is lower than Apollo’s 60.3, Manipal’s 110.12, Max’s 67.27, Fortis’ 65.63 and Aster DM’s 207.39. Its P/B of 2.84 is also below each of those peers, whose price-to-book multiples range from 5.39 to 13.31. By that measure, the stock sits at a lower book-value multiple than these larger listed names.

Returns are mixed rather than uniformly strong or weak. The company’s ROE of 10.62% is below Apollo, Manipal, Max and Fortis, but above Aster DM. Its ROCE of 14.42% is below Apollo and Max, while above Manipal, Fortis and Aster DM. That leaves Nephro Care India Share Price positioned as a smaller-scale, lower-multiple stock with middle-of-the-pack returns against selected peers.

Why Investors Are Watching Nephro Care India

• The stock fell 9.93% in a single session to Rs 90.7 from Rs 100.7.
• It traded between Rs 100 and Rs 85.35 during the day, showing a wide intraday range.
• P/E of 49.28 is close to the industry median of 47.77.
• P/B of 2.84 is below the industry median of 4.12.
• ROE of 10.62% and ROCE of 14.42% indicate moderate profitability relative to benchmark medians.
• At Rs 166.02 crore market cap, it remains much smaller than major Healthcare peers.

About Nephro Care India

Nephro Care India operates in the Healthcare sector and is classified under Hospital & Healthcare Services. Based on the supplied market-cap category, it is a Micro Cap company. That smaller scale can sometimes coincide with sharper price swings than are typically seen in much larger listed hospital operators, although the dataset here does not state a specific reason for today’s move.

Track Nephro Care India Share Price on Univest

Use Nephro Care India (NEPHROCARE-SM) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

On Univest, investors can follow Nephro Care India Share Price alongside valuation ratios, technical indicators where available, sector comparisons and peer metrics. That broader view helps place a one-day decline in context instead of treating price action alone as a complete investment signal.

Frequently Asked Questions

Why did Nephro Care India Share Price fall today?

Ans.  The stock fell 9.93% to Rs 90.7 from the previous close of Rs 100.7. The supplied data confirms the decline, but it does not establish a company-specific catalyst behind today’s move.

What is Nephro Care India Share Price today?

Ans.  The stock price in the supplied data is Rs 90.7. It was down Rs 10 on the day after opening at Rs 100 and trading between Rs 100 and Rs 85.35.

What does today’s price action show?

Ans.  It shows that the stock opened at Rs 100, could not hold that level, and moved down to an intraday low of Rs 85.35 before trading at Rs 90.7. The previous close was Rs 100.7.

What is the P/E ratio of Nephro Care India?

Ans.  The company’s P/E ratio is 49.28, which is slightly above the same-industry median P/E of 47.77 and below the industry average of 102.53. The company trades at a P/E ratio of 49.28x.

What is the P/B ratio of Nephro Care India?

Ans.  Its P/B ratio is 2.84, lower than the same-industry median of 4.12 and average of 4.71 in the supplied benchmark data. The company trades at a P/E ratio of 49.28x.

How profitable is the company on ROE and ROCE?

Ans.  ROE is 10.62% and ROCE is 14.42%. Both are below the benchmark medians of 12.88% and 15.77% respectively, while ROCE is above the stated benchmark average of 3.29%. ROE stands at 10.62%.

How does it compare with larger Healthcare peers?

Ans.  It is far smaller by market cap than Apollo Hospitals, Manipal Health, Max Healthcare, Fortis Healthcare and Aster DM Healthcare. Its P/E and P/B are lower than those peers, while its return ratios are mixed in comparison.